Cannabinoids have been widely known to treat a wide range of human disorders such as obesity and psychological disorders. Cannabinoids are situated normally in the marijuana plant (cannabis sativa). Cannabinoids involve chemicals such as tetrahydrocannabinol (THC) and cannabinol (CBD).
THC is a psychoactive molecule. As the term suggests, this is the one that causes the high, or “stoned” feeling when consumed or smoked in adequate quantities. CBD on the other hand is non-psychoactive. Both THC and CBD are being investigated as treatments for a whole range of different conditions. This is due to their interaction with the endocannabinoid system in the body.
The endocannabinoid system has two cannabinoid receptors, 1 and 2. These allow endogenous cannabinoids to bind and work throughout the body. This paper looks at how cannabinoids can be used to affect the amount of food a human intakes and obesity.
The current report looks at the different lines of evidence suggesting that cannabinoid receptor 1 antagonists, involving the prototype Rimonabant, decrease food intake and body size in laboratory animals. Recent clinical experiments showed that Rimonabant decreased body size also in people with obesity. Therapy with rimonabant was related to a positive impact on various metabolic parameters and cardiovascular danger factors associated with obesity. The results evaluated in this report indicate that cannabinoid receptor 1 antagonists may comprise of a normal class of drugs that are plausible as an efficient therapy for obesity-associated syndromes.
Most side-effects like insomnia and headaches were reported by people and this was frequent in most treatments. People being administered 20 mg rimonabant said that dizziness, nausea, diarrhea, anxiety, and depression were more frequent with this treatment. Some of the patients chose to withdraw from the study because of these side effects.
The conclusion of the experiments has opened up a brand new plan for the therapy of obesity and associated metabolic syndromes. It is of intrigue that Rimonabant treatment might also cause a decrease in tobacco smoking and, at least in laboratory models, a decrease in the intake of alcohol. Rimonabant is now under clinical review in America for its function to decrease alcohol intake in alcoholics. Should all these initial trials be given the green light, Rimonabant will be an agent with a rather wide spectrum of therapeutic application. More results are, however, needed to further confirm its therapeutic effectiveness, application, and safety.
Overall, when endocannabinoid levels are normal, energy balance is received in humans and this can lead to the anti-obesity effects and reduction of body fat in obese mice. The treatment of obesity with cannabinoids can lead to feeding behavior changes. The side effects in diet induced obese mice were minimal.